1002 related articles for article (PubMed ID: 17442797)
1. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
[TBL] [Abstract][Full Text] [Related]
2. [Species distribution and antifungal susceptibilities of yeast clinical isolates from three hospitals in Korea, 2001 to 2007].
Lee MK; Yong D; Kim M; Kim MN; Lee K
Korean J Lab Med; 2010 Aug; 30(4):364-72. PubMed ID: 20805708
[TBL] [Abstract][Full Text] [Related]
3. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Rinaldi MG; Barnes R; Hu B; Veselov AV; Tiraboschi N; Nagy E; Gibbs DL
J Clin Microbiol; 2005 Dec; 43(12):5848-59. PubMed ID: 16333066
[TBL] [Abstract][Full Text] [Related]
4. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
Pfaller MA; Diekema DJ; Colombo AL; Kibbler C; Ng KP; Gibbs DL; Newell VA
J Clin Microbiol; 2006 Oct; 44(10):3578-82. PubMed ID: 17021085
[TBL] [Abstract][Full Text] [Related]
5. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ellis D; Tullio V; Rodloff A; Fu W; Ling TA;
J Clin Microbiol; 2010 Apr; 48(4):1366-77. PubMed ID: 20164282
[TBL] [Abstract][Full Text] [Related]
6. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole.
Lee SC; Lo HJ; Fung CP; Lee N; See LC
J Microbiol Immunol Infect; 2009 Apr; 42(2):148-53. PubMed ID: 19597647
[TBL] [Abstract][Full Text] [Related]
7. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
Quindós G; Sánchez-Vargas LO; Villar-Vidal M; Eraso E; Alkorta M; Hernández-Almaraz JL
Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468
[TBL] [Abstract][Full Text] [Related]
8. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Barton R; Bijie H; Bille J; Chang SC; da Luz Martins M; Duse A; Dzierzanowska D; Ellis D; Finquelievich J; Gould I; Gur D; Hoosen A; Lee K; Mallatova N; Mallie M; Peng NG; Petrikos G; Santiago A; Trupl J; VanDen Abeele AM; Wadula J; Zaidi M;
Diagn Microbiol Infect Dis; 2010 Jun; 67(2):162-71. PubMed ID: 20338711
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of fluconazole and voriconazole against clinical isolates of Candida spp. by E-test method.
Madhavan P; Jamal F; Chong PP; Ng KP
Trop Biomed; 2010 Aug; 27(2):200-7. PubMed ID: 20962716
[TBL] [Abstract][Full Text] [Related]
10. In vitro fluconazole susceptibility of 1565 clinical isolates of Candida species evaluated by the disk diffusion method performed using NCCLS M44-A guidelines.
Testore GP; Dori L; Buonomini AR; Schito GC; Soro O; Fortina G; Andreoni S; Carlone N; Tullio V; Andreoni M
Diagn Microbiol Infect Dis; 2004 Nov; 50(3):187-92. PubMed ID: 15541604
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion.
Hazen KC; Baron EJ; Colombo AL; Girmenia C; Sanchez-Sousa A; del Palacio A; de Bedout C; Gibbs DL;
J Clin Microbiol; 2003 Dec; 41(12):5623-32. PubMed ID: 14662952
[TBL] [Abstract][Full Text] [Related]
12. Comparison of disk diffusion test and Etest for voriconazole and fluconazole susceptibility testing.
Buchta V; Vejsova M; Vale-Silva LA
Folia Microbiol (Praha); 2008; 53(2):153-60. PubMed ID: 18837162
[TBL] [Abstract][Full Text] [Related]
13. Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Sep; 65(1):27-34. PubMed ID: 19679232
[TBL] [Abstract][Full Text] [Related]
14. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Bijie H; Dzierzanowska D; Klimko NN; Letscher-Bru V; Lisalova M; Muehlethaler K; Rennison C; Zaidi M;
J Clin Microbiol; 2009 Jan; 47(1):117-23. PubMed ID: 19005141
[TBL] [Abstract][Full Text] [Related]
15. [Disk diffusion method for fluconazole susceptibility testing of Candida spp. isolates].
Rodero L; Córdoba S; Vivot W; Campo M; Corfield P; Olguín C; Cuirolo A; Soria M; Guelfand L; Canteros CE; Davel G;
Rev Argent Microbiol; 2006; 38(3):155-63. PubMed ID: 17152217
[TBL] [Abstract][Full Text] [Related]
16. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of voriconazole against Candida species isolated in Taiwan.
Yang YL; Cheng HH; Lo HJ
Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
[TBL] [Abstract][Full Text] [Related]
18. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
19. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
